Arcus Biosciences (RCUS) 10-Q2024 Q1 Quarterly report

Filed: 8 May 24, 4:08pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. junior Good

New words: abstract, activist, Addendum, agency, AI, allegedly, alleviate, American, April, arbitration, artificial, AXL, basic, Biosecure, bound, Canada, cas, casdatifan, CASL, charge, chemo, Chinese, colorectal, committed, concurrent, creation, credibility, cutoff, deceptive, deficient, degradation, depleted, deploying, detrimental, DLT, Electronic, equivalent, escalation, Europe, expenditure, Extortion, forecasted, Framework, GDPR, Goeltz, hardware, honor, hypothetical, incident, intelligence, kinase, leaked, lease, leased, living, mainland, median, MHMD, misrepresentative, model, monumental, noncompliance, oral, oxaliplatin, persistent, PIPEDA, PIPL, platform, provincial, RCC, regularly, relocate, reserve, retaliatory, revealed, Robert, Society, software, sterling, strict, sublease, sue, Synthetic, team, temporary, transcription, tyrosine, UK, unallocated, unchanged, Washington, zanza, zanzalintinib

Removed: alter, altered, analytical, approving, batch, BMS, bridging, budget, Cayman, choosing, computer, consistent, contractor, cornerstone, correct, debarred, deletion, delivering, denial, document, documentation, emergence, encouraging, excluding, execute, exfiltrate, FCA, forming, formulation, fundraising, good, guide, hinder, HITECH, hold, impacted, impacting, Innovation, Institutional, intermittently, intrusion, invested, Japan, Justice, lockup, losing, mark, medication, monitoring, noting, operationalized, optimize, outlining, outsource, participating, partner, penalized, performing, periodic, play, Poor, precluding, prioritization, produced, production, put, reaching, recall, recruiting, reexamination, refusing, regulated, relieve, repayment, repetition, requesting, responsibility, resubmit, retaining, role, schedule, screen, shut, stability, standstill, stricter, subjecting, submitting, substance, substitute, suspending, temporarily, terminating, treating, Union, unreasonable, unreliable, withdraw, withdrawing, yield

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated RCUS transcripts

RCUS similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Arcus Biosciences, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 8, 2024	By:	/s/ Robert C. Goeltz II
		Robert C. Goeltz II
		Chief Financial Officer (Principal Financial Officer)